Kailera Therapeutics, Inc. KLRA
12.97 USD +0.80 (+6.57%)
At closeNov 6, 2026, 6:22 PM EST
13.31 +0.34 +2.62%
After hours · Nov 6, 6:22 PM ET
11.97 Day range 13.26
10.00 52-week range 26.00
- YTD
- -50.12%
- 1 year
- -50.12%
- Market cap
- 1.68B
- EPS (ttm)
- -4.16
- Shares out
- 129.85M
- Forward P/E
- -3.02
- YTD return
- -50.12%
- 1-year return
- -50.12%
- Volume
- 733.27K
- Avg volume
- 1.06M
- Open
- 12.29
- Previous close
- 12.17
- Day's range
- 11.97 – 13.26
- 52-week range
- 10.00 – 26.00
- Price target
- 42.75 (+229.6%)
- Earnings date
- Mar 26, 2027
5D +0.04 (+0.31%)
Key statistics
- Enterprise value
- 752.91M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 916.74M
- Total debt
- 10.22M
- Return on equity
- 0.00%
- Short % of float
- 6.41%
- 50-day average
- 12.89
- 200-day average
- 17.82
Analyst view
Price target (mean) 42.75 +229.6% upside
Now 12.97
- Target (low)
- 30.00
- Target (mean)
- 42.75
- Target (high)
- 57.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy1
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 26, 2027
Expected Mar 26, 2027. Consensus EPS estimate -1.16.
Financials — quick view
KLRA Revenue — quarterly 0
KLRA Net income — quarterly -95.67M
KLRA EPS — quarterly -0.74
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 26, 2027 | Mar 30, 2027 | -1.10 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -1.55 | -0.74 | +0.81 | +52.26% |
| Aug 12, 2026 | Jun 30, 2026 | -0.89667 | -1.09 | -0.19 | -21.56% |
| May 26, 2026 | Mar 31, 2026 | -0.775 | -3,650.00 | -3,649.22 | -470,867.74% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 2026 | Leerink Partners | init | — | Outperform |
| May 12, 2026 | Jefferies | init | — | Buy |
| May 12, 2026 | Evercore ISI Group | init | — | Outperform |
| May 12, 2026 | JP Morgan | init | — | Overweight |
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kailera.com
News
Kailera Therapeutics Q3 EPS $(0.74) Beats $(1.02) Estimate 
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates 
Kailera Therapeutics to Participate in November Investor Conferences 
Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028 
Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’ - Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Why Is Kailera Therapeutics Stock Falling Tuesday? - Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China
Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M 
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
Your note
Sign in to keep a note on KLRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIN CAPITAL INVESTORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| JIANGSU HENGRUI PHARMACEUTICALS CO. LTD. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 19, 2026 | 2,034,130 |
| KAPLAN ANDREW T | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| KOPPEL ADAM M | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Apr 19, 2026 | 0 |
| RENAUD RONALD C JR | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 8, 2026 | 38,094 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Investors Llc | 20.25% | 26,255,581 | 340.53M | Jun 29, 2026 |
| Bain Capital Life Sciences Investors, LLC | 17.42% | 22,583,268 | 292.90M | Jun 29, 2026 |
| RTW Investments LP | 8.31% | 10,776,820 | 139.78M | Jun 29, 2026 |
| Canada Pension Plan Investment Board | 5.63% | 7,304,688 | 94.74M | Jun 29, 2026 |
| Atlas Venture Life Science Advisors, LLC | 3.99% | 5,171,282 | 67.07M | Jun 29, 2026 |
| FMR, LLC | 3.06% | 3,970,865 | 51.50M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.69% | 2,191,928 | 28.43M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.28% | 1,657,199 | 21.49M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.94% | 1,221,869 | 15.85M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.93% | 1,199,783 | 15.56M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.91% | 1,180,411 | 15.31M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.70% | 904,283 | 11.73M | Jun 29, 2026 |